Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety - Viking Therapeutics ( NASDAQ:VKTX )

a week ago

Viking Therapeutics Inc VKTX announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations at ObesityWeek 2024. Viking is evaluating both subcutaneous and oral formulations of VK2735 in clinical trials.

Ticker	Sentiment	Impact
VKTX	Neutral	24 %